Judge Karen Marston is overseeing lawsuits filed by people who allege Wegovy increased their risk of developing NAION
GLP-1 inhibits glucagon secretion when plasma glucose concentration is high, while GIP acts at lower glucose levels
Researchers suggested as a result of these findings that the peptide may have acted to decrease cell death in cardiomyocytes, as well as improve production of extracellular matrix components and angiogenesis to damaged tissue
Which is why our decision to phase out coverage of glucagon-like peptide 1 (GLP-1) weight loss drugs such as Wegovy, Zepbound and Saxenda for large group, fully insured members has been so difficult
Therefore, you should thoroughly consult a qualified healthcare professional in Tampa before undergoing this treatment
Thyroid Tumors: Animal studies suggest a potential risk for certain thyroid tumors, though the relevance to humans is still under investigation